HS-130

HS-130: Our Next-generation Allogeneic Cell-based Drug

HS-130 ComPACT™ (Combination Pan-antigen Cytotoxic Therapy) is our next-generation allogeneic cell-based drug designed to secrete tumor-associated antigens along with an OX-40 co-stimulator designed to enhance T-cell activation and memory response. ComPACT is the first potential, dual acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. ComPACT helps unlock the body’s natural defenses and builds upon ImPACT by also providing co-stimulation to enhance T-cell activation and expansion.

Combination Therapies Indication Preclinical Phase 1 Phase 2 Phase 3 Market Comments

HS-130

(viagenpumatucel-L)

NSCLC
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
ComPACT™ activation technology in combination with checkpoint inhibitors TBA